Pancreatic Cancer Clinical Trials

• Patients with measurable and pathologically confirmed advanced pancreatic cancer, including metastatic pancreatic cancer (who have received standard chemotherapy) and recurrent pancreatic cancer (who have received surgery and adjuvant chemotherapy previously).

• Patient's tumor must express the KRAS G12V mutation, or a G12V mutation in HRAS or NRAS, as determined by DNA or RNA sequencing methods.

• Patients must be HLA-A\*11:01.

• Patients with brain metastasis may be eligible if they are asymptomatic and there are fewer than 3 brain lesions that are each less than 1 cm in diameter.

• Patients between 18 to 75 years old are eligible.

• Patients should have good clinical performance status (ECOG 0 or 1).

• Patients must practice birth control once enrolled into the study and for up to four months after therapy.

• Patients must be seronegative for HIV antibody.

• Patients must be seronegative for hepatitis B surface antigen and core antibody (or HBV non-detectable by QPCR).

• Patients must be seronegative for hepatitis C antibody (or HCV non-detectable by QPCR).

• Baseline hematology criteria:

‣ Absolute neutrophil count of at least 1000/mm\^3.

⁃ White blood cell count of at least 3000/mm\^3.

⁃ Platelet count of at least 100,000/mm\^3.

⁃ Hemoglobin \> 8.0 g/dL.

• Baseline chemistry criteria:

‣ Serum ALT/AST less than or equal to 3.0 x ULN.

⁃ Total bilirubin less than or equal to 1.5 mg/dL, unless the patient has Gilbert's Syndrome in which case total bilirubin must be less than or equal to 3.0 mg/dL.

⁃ Serum creatinine less than or equal to 1.6 mg/dL.

• Anticipated lifespan greater than 12 weeks.

• Patients must be willing and able to comply with all study-related procedures and follow-up requirements.

• Patients must be able to understand and sign a written Informed Consent Document as well as a durable power of attorney.